Pharming Group N.V.
Yahoo Finance • 6 days ago
Biggest stock movers Tuesday: SMMT, NVTS, and more
[Data analysis graph background, market investment trend, global economic analysis] Donny DBM Stock futures inched lower in the premarket hours of Tuesday as market participants weighed a continued surge in government bond yields against... Full story
Yahoo Finance • 6 days ago
Pharming announces CEO transition
Pharming Group N.V. Leiden, the Netherlands, September 29, 2026: Pharming (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announced that the Board of Directors an... Full story
Yahoo Finance • 24 days ago
Pharming wins approval of Joenja for younger age group
[FDA approved. Seal and imprint] Waldemarus * The US FDA has approved Pharming Group's (PHAR [https://seekingalpha.com/symbol/PHAR]) Joenja (leniolisib) for children between the ages of four and 11 with a kind of rare genetic immune sys... Full story
Yahoo Finance • 2 months ago
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Pharming Group (PHAR)
NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Pharming Group (NASDAQ: PHAR) stock dropped 22% on July 30, 2026, after the Company reported second-quarter revenue of $90.2 million -- down 3% year-over-year -- and cut its full-year 2026 reve... Full story
Yahoo Finance • 2 months ago
Pharming Group to participate in Canaccord Genuity 46th Annual Growth Conference
Leiden, the Netherlands, August 4, 2026: Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR), today announced its participation in the Canaccord Genuity 46th Annual Growth Conference in Boston on August 12-13, 2026. Michael Levit... Full story
Yahoo Finance • 2 months ago
Form 8.5 (EPT/RI) - Pharos Energy Plc
PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the “Code” 1. KEY INFORMATION (a) Name of exempt principal tra... Full story
Yahoo Finance • 2 months ago
Pharming (PHAR) Q2 2026 Earnings Call Transcript
Image source: The Motley Fool. DATE Thursday, July 30, 2026 at 7:30 a.m. ET CALL PARTICIPANTS Chief Executive Officer - Fabrice ChouraquiChief Commercial Officer - Leverne MarshChief Medical Officer - Anurag RelanChief Financial Office... Full story
Yahoo Finance • 2 months ago
Pharming Group Q2 Earnings Call Highlights
Key Points Interested in Pharming Group N.V. Sponsored ADR? Here are five stocks we like better. Pharming cut its 2026 outlook, forecasting revenue of $375 million to $395 million after second-quarter revenue fell 3% to $90.2 million. The... Full story
Yahoo Finance • 2 months ago
Pharming GAAP EPS of $0.00 misses by $0.06, revenue of $90.2M misses by $9.32M
* Pharming press release [https://seekingalpha.com/filing/309877635] (PHAR [https://seekingalpha.com/symbol/PHAR]): Q2 GAAP EPS of $0.00 misses by $0.06. * Revenue of $90.2M (-3.2% Y/Y) misses by $9.32M. * For the second quarter of 2... Full story
Yahoo Finance • 2 months ago
Pharming Q2 Preview: Can Joenja Help Swing Back To Profit, Offsetting Ruconest Weakness?
(RTTNews) - Pharming Group N.V. (PHAR) announced that it will release preliminary results for the second quarter of fiscal 2026 along with business update on July 30, 2026. The company's management will host a conference call at 13:30 CEST... Full story
Yahoo Finance • 3 months ago
Pharming Group to report second quarter and first half 2026 financial results and provide business update on July 30
Leiden, the Netherlands, July 16, 2026: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will report its preliminary (unaudited) financial results for the second quarter and first half 2026 and pro... Full story
Yahoo Finance • 4 months ago
Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDS
If approved, Joenja will be the first approved treatment in the U.S. for children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare primary immunodeficiency Supplemental New Drug Application (sNDA) resubmission... Full story
Yahoo Finance • 4 months ago
Pharming Group Receives EU Approval For Joenja In Rare Immunodeficiency
(RTTNews) - Pharming Group (PHAR) announced that the European Commission granted marketing authorization for Joenja (leniolisib), an oral, selective phosphoinositide 3-kinase (PI3K) delta inhibitor, for the treatment of activated PI3K delt... Full story
Yahoo Finance • 5 months ago
Pharma Equity Groups datterselskab Reponex tager vigtigt skridt fremad inden for inflammatorisk tarmsygdom med kommende europæisk patentgodkendelse
Pharma Equity Groups datterselskab Reponex tager vigtigt skridt fremad inden for inflammatorisk tarmsygdom med kommende europæisk patentgodkendelse 11. maj 2026 Meddelelse nr. 7 Pharma Equity Group A/S meddeler i dag, at selskabet... Full story
Yahoo Finance • 5 months ago
Pharming Group announces presentations at CIS 2026 Annual Meeting, including leniolisib pediatric data in APDS and clinical experience in CVID and related disorders
Leiden, the Netherlands, May 7, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) today announced presentations at the 2026 Annual Meeting of the Clinical Immunology Society (CIS), taking plac... Full story
Yahoo Finance • 5 months ago
Pharming Group to report first quarter 2026 financial results and provide business update on May 7
Leiden, the Netherlands, April 23, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will report its preliminary (unaudited) financial results for the first quarter 2026 and p... Full story
Yahoo Finance • 6 months ago
Pharming Group announces the 2026 Annual General Meeting of Shareholders
Leiden, the Netherlands, April 16, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) today announced that the Company’s 2026 Annual General Meeting of Shareholders (the “AGM”) will be held o... Full story
Yahoo Finance • 6 months ago
Pharming Group announces the filing of its 2025 Annual Report and Form 20-F
Leiden, the Netherlands, April 2, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) today announced the filing of its Annual Report for the year ended December 31, 2025. The Annual Report is... Full story
Yahoo Finance • 6 months ago
Pharming Group receives positive CHMP opinion for Joenja® (leniolisib) for the treatment of APDS in adult and pediatric patients 12 years and older
If approved, Joenja® (leniolisib) would become the first approved treatment in the European Union for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare primary immunodeficiencyDecision based on Phase II/III clinical... Full story
Yahoo Finance • 7 months ago
Pharming Group Q4 Earnings Call Highlights
Pharming Group logo Pharming Group (NASDAQ:PHAR) reported what management described as a strong finish to 2025, highlighting double-digit revenue growth, a return to operating profitability, and expanding commercial traction for both RUCO... Full story